Applied Therapeutics Inc (APLT) - Total Assets
Based on the latest financial reports, Applied Therapeutics Inc (APLT) holds total assets worth $34.37 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See APLT net asset value for net asset value and shareholders' equity analysis.
Applied Therapeutics Inc - Total Assets Trend (2017–2024)
This chart illustrates how Applied Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Applied Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Applied Therapeutics Inc's total assets of $34.37 Million consist of 96.5% current assets and 3.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 91.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Applied Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Applied Therapeutics Inc (APLT) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Applied Therapeutics Inc's current assets represent 96.5% of total assets in 2024, a decrease from 100.0% in 2017.
- Cash Position: Cash and equivalents constituted 91.6% of total assets in 2024, down from 99.7% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Applied Therapeutics Inc Competitors by Total Assets
Key competitors of Applied Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Applied Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.96 | 1.06 | 4.83 |
| Quick Ratio | 0.96 | 1.06 | 4.60 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.25 Million | $5.64 Million | $81.36 Million |
Applied Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Applied Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.72 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | 58.1% |
| Total Assets | $86.69 Million |
| Market Capitalization | $14.86 Million USD |
Valuation Analysis
Below Book Valuation: The market values Applied Therapeutics Inc's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Applied Therapeutics Inc's assets grew by 58.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Applied Therapeutics Inc (2017–2024)
The table below shows the annual total assets of Applied Therapeutics Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $86.69 Million | +58.10% |
| 2023-12-31 | $54.83 Million | +42.93% |
| 2022-12-31 | $38.36 Million | -57.32% |
| 2021-12-31 | $89.89 Million | -13.98% |
| 2020-12-31 | $104.51 Million | +115.97% |
| 2019-12-31 | $48.39 Million | +139.01% |
| 2018-12-31 | $20.25 Million | +516.13% |
| 2017-12-31 | $3.29 Million | -- |
About Applied Therapeutics Inc
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric cli… Read more